HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today ...
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...
Adeno-associated virus (AAV) vectors may be the best option to deliver genetic cargo to cells in the body. But they are far from perfect. They require large doses, hold small amounts of cargo, and can ...
For the most part, viral vector–based gene therapies have been used against rare diseases. But now these gene therapies are also starting to be used against diseases that have larger patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results